FRACTIONATED BDD SERIES



1.0

Mainpro+ Group Learning MOC Section 1

Learning Objectives for the series

- 1. Develop an approach to the work up of patients with suspected blood disorders, especially those with laboratory abnormalities (e.g. anemia or other cytopenias).
- 2. Use clinical algorithms to inform the diagnosis, management, and optimal referral of patients with blood disorders.
- 3. Review up to date treatment strategies for patients with common blood disorders.

Note: This event is ONLINE ONLY.

You will receive a link to connect before the session date.

This series is presented in cooperation with the Community Oncology Program at CancerCare Manitoba.

Register here: cpd-umanitoba.com



y of | 🙀 Univer ces | 🥰 ≝Mani

Throughout this series, local hematologists will lead educational sessions and provide practical and relevant information on topics related to the workup and management of blood disorders in a primary care setting.

SESSION 1 – MAY 1, 2020 THE IRON CHEFS: SERVING UP HIGH QUALITY CARE IN THE SETTING OF IRON DEFICIENCY AND OVERLOAD

LEARNING OBJECTIVES:

- Explain the mechanisms by which the body regulates iron homeostasis, and how defects can lead to iron overload
- Use simple tests (iron, TIBC, and ferritin) to sort out disorders of altered iron status
- · Apply strategies to manage iron deficiency and iron overload

SPEAKERS:

Emily Rimmer, MD, FRCPC

Hematologist, CancerCare Manitoba Assistant Professor, Department of Internal Medicine, Section of Haematology/Oncology, University of Manitoba

Donald Houston, MD, PhD, FRCPC

Hematologist, CancerCare Manitoba Affiliate Investigator, Research Institute of Oncology and Hematology, CancerCare Manitoba Associate Professor, Department of Internal Medicine, Section of Haematology/Oncology, University of Manitoba

SESSION 2 – MAY 22, 2020 MGUS & MYELOMA

LEARNING OBJECTIVES:

- Describe indications for ordering a serum protein electrophoresis (SPEP) and free light chain ratio and how to interpret results
- Distinguish MGUS from multiple myeloma and other plasma cell dyscrasias
- Summarize current treatment options and prognosis for multiple myeloma in 2020

SPEAKERS:

Vi Dao MD, FRCPC

Hematologist, CancerCare Manitoba Assistant Professor, Department of Internal Medicine, Section of Haematology/Oncology, University of Manitoba Mark Kristjanson, MD, CFPC

Primary Care Lead, CancerCare Manitoba

Arvand Barghi, MD, FRCPC Currently completing hematology subspecialty residency

